相关实验视频

Updated: May 29, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

在肺癌细胞中,GRHL2-HER3和E-cadherin介导EGFR绕道药物抵抗

Fumiya Ito¹, Wakiko Iwata¹, Yoshihiro Adachi¹

¹Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Frontiers in cell and developmental biology

|February 3, 2025

概括

肺癌中耐药性是最大的挑战. 这项研究表明,转录因子GRHL2和增加的E-cadherin驱动对ERLOTINIB等EGFR抑制剂的耐药性,这表明新的组合疗法.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物耐药性机制药物耐药性机制

背景情况:

表皮生长因子受体 (EGFR) 是癌症治疗的关键标,特别是肺癌.
对EGFR抑制剂的耐药性,如erlotinib,是一个重要的临床挑战,限制了治疗疗效.
了解导致获得性抗性的分子机制对于开发有效的治疗策略至关重要.

研究的目的:

研究肺癌细胞中对埃洛尼布获得的耐药性机制.
为了确定克服埃洛尼布耐药性的新分子标.
探索GRHL2,HER3和E-cadherin在埃洛提尼布耐药性中的作用.

主要方法:

通过长时间暴露于药物,建立了抗埃洛提尼布 (ER) 肺癌细胞系 (A549).
RNA测序以识别ER细胞中差异表达的基因.
基因淘汰和淘汰实验,以评估已识别的基因 (GRHL2,HER3,E-cadherin) 的功能作用.
细胞-细胞粘附测试和IC50测量以量化药物耐药性.

主要成果:

ER细胞表现出对erlotinib的耐药性增加,EGFR水平降低,瘤生长增加.
转录因子GRHL2的升级被确定为对erlotinib耐药性的关键驱动因素.
GRHL2通过上调受体氨酸激酶 HER3 的调节来促进耐药性.
通过高调节的E-cadherin调节的细胞-细胞粘附度增加,也导致了对erlotinib的耐药性,这在很大程度上独立于GRHL2.

结论:

肺癌中获得的埃洛提尼布耐药性涉及多个并行途径,包括GRHL2-HER3信号传递和E-cadherin介导的细胞-细胞粘附.
针对GRHL2-HER3和E-cadherin通路可能是必要的,以克服对erlotinib的耐药性.
这些发现为药物耐药性机制提供了新的见解,并提出了肺癌治疗的潜在组合疗法.

关键词:

欧洲农业基金会 (EGFR) 是一个基金.GRHL2 GRHL2 的时间在HER3中,HER3是HER3.卡德林是个非常有趣的人.药物耐药性耐药性药物耐药性肺癌是一种肺癌.

更多相关视频

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...